Eyestem Partners up with RetinAI to Innovate Clinical Research

Bengaluru-based biotechnology company, Eyestem Research, has recently formed a strategic partnership with Ikerian AG and RetinAI Inc. The company focuses on cell therapy approaches in their research activities. US-based company RetinAI is a trailblazer in the field of ophthalmology, specializing in clinical and imaging data management software along with advanced AI-driven analytics. RetinAI's discovery platform and AI tools hold the potential to accelerate Eyestem's mission of transforming treatment for geographic atrophy through their groundbreaking cell therapy, Eyecyte-RPE.

The integration of the AI tools and RetinAI discovery platform with Eyestem's vision has been observed to have a perfect fit by Dr. Jogin Desai, the founder and CEO of the company. This promising collaboration has the potential to reduce the time required for clinical trials and improve the accuracy of data analysis. This collaboration is more than just a partnership. It represents the merging of advanced biotech innovation and artificial intelligence with the purpose of rewriting the story for patients worldwide who are impacted by geographic atrophy, as per pharmabiz. Dr. C++. According to Carlos Ciller, CEO of RetinAI, their AI-driven Discovery platform is positioned to greatly expedite research efforts and offer improved understanding of disease progression and outcomes. Together, we are certain that this combination of forces will not only enhance understanding in the creation of innovative therapies but also result in the expedited provision of life-changing remedies to individuals suffering from retinal diseases worldwide. Geographic atrophy, a global health concern, is a severe manifestation of dry age-related macular degeneration (AMD). As of now, approximately 200 million individuals worldwide suffer from dry AMD, leading to permanent vision impairment. The prevalence of this serious eye disease is increasing rapidly, and is further exacerbated by an aging population.